Tau Brain Scans in Late-Onset Psychosis Among Older Adults
Studies tau brain scans and blood markers in older people with new hallucinations or delusions.
Plain-language title generated from the registry record
Registry title: Tau Biomarkers in Late-onset Psychosis (LOP)
Key facts
- Where
- Manhasset, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 85 years old?
Source: NCT06336382, who can take part
Where in United States
- The Feinstein Institutes for Medical ResearchManhasset, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jeremy Koppel
- Trial code
- NCT06336382
- Record updated
- 5 November 2026
- Original description
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.Read full original descriptionShow less
Tau Biomarkers in Late-onset Psychosis (LOP)
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Inclusion: Male or female, aged 65-85 years; Diagnosis of late-onset non-affective primary psychotic disorder consistent with either very late-onset schizophrenia-like psychosis (VLOSP, International Late-Onset Schizophrenia Group consensus criteria, Howard et al., 2000) or delusional disorder (DSM-5 criteria); Caregiver available to provide collateral history and participation in informant-based ratings (NPI,CDR); Clinical Dementia Rating (CDR) score of 0 or 0.5; Mini-Mental State Examination (MMSE) score ≥ 24 and at the screening visit; Normal memory function (to rule-out mild cognitive impairment, MCI) documented by scoring within 1.5 SD range in education adjusted norms of the Logical Memory II subscale; Ability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation (hearing aids permitted).
Exclusion: Presence of metal implants such as pacemakers, ear implants, internal bullet fragments or shrapnel; Participants with affective and psychotic disorders including bipolar disorder, schizoaffective disorder, active major depression; insulin dependent type 2 diabetes; a history of CVD; a history of epilepsy; a history of TBI with greater than 15 minutes of loss of consciousness; a movement disorder including Parkinson's disease; stroke; autoimmune disease affecting the CNS; substance abuse disorder; or active delirium/encephalopathy; Evidence of a clinically relevant neurological disorder; History of alcoholism or drug dependency/abuse within the last 5 years before screening; Hearing impairment as evidenced by the inability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation. Subjects with hearing aids will be allowed to participate if they meet minimum hearing requirements; Modified Hachinski ischemia score of more than 4; Inability to lie flat for 1 hour approximately.